[Percutaneous treatment of mitral regurgitation]

Ann Cardiol Angeiol (Paris). 2019 Dec;68(6):468-473. doi: 10.1016/j.ancard.2019.09.023. Epub 2019 Oct 22.
[Article in French]

Abstract

Mitral regurgitation (MR) is currently the most frequent valvular heart disease, and the second most operated valve in Europe. Around 50% of patients presenting severe MR are denied surgery, despite the adverse prognosis associated with the absence of treatment, due to comorbidities and/or advanced age. During the previous years, percutaneous treatment of MR, whether by replacement or, more frequently, by repair, has been developed, providing an alternative for those patients who are deemed at prohibitive, but also, high surgical risk. Percutaneous edge-to-edge repair is currently the most frequently used technique, and is the only one recommended by the European Guidelines for Valvular Heart Disease Management. In the current article, we review the different strategies for MR repair, as well as the indications and level of evidence for their use.

Keywords: Fuite Mitrale; Mitral regurgitation; Mitral repair; Mitral replacement; Percutaneous treatment; Remplacement mitral; Réparation mitrale; Traitement percutané.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged, 80 and over
  • Female
  • Heart Valve Prosthesis Implantation / methods*
  • Humans
  • Medical Illustration
  • Mitral Valve / diagnostic imaging
  • Mitral Valve / surgery*
  • Mitral Valve Insufficiency / classification
  • Mitral Valve Insufficiency / diagnostic imaging
  • Mitral Valve Insufficiency / etiology
  • Mitral Valve Insufficiency / surgery*
  • Polysaccharides
  • Practice Guidelines as Topic

Substances

  • Polysaccharides
  • SHU 454